NEW YORK (GenomeWeb News) – Diagnostics developer Miraculins has agreed to license a panel of biomarkers from Mount Sinai Hospital that it will use to develop diagnostic assays to detect preecleampsia, the company said today.
These markers have shown evidence that they may help to diagnose the disease in its earliest stages, Winnipeg, Manitoba-based Miraculins said.